Wu Chin-Chen
Department of Pharmacology, National Defense Medical Center, Neihu, Taipei, Taiwan, ROC.
Acta Anaesthesiol Taiwan. 2012 Jun;50(2):74-7. doi: 10.1016/j.aat.2012.05.003. Epub 2012 Jun 19.
For many years, basic research with relatively straightforward pathophysiologic approaches has driven clinical trials using molecules that supposedly interfere positively with inflammatory processes. However, most of these trials have failed to demonstrate any outcome benefit. Indeed, we need to revisit current paradigms and to think about the possibility that outcome may be predetermined in severe sepsis or septic shock. In addition, an early diagnosis of sepsis prior to the onset of clinical decline is also of particular interest to health practitioners because this information increases the possibilities for early and specific treatment of this life threatening condition. Indeed, the time to initiate therapy is thought to be crucial and the major determent factor in surviving sepsis. Despite substantial progress in sepsis therapy, the gap between the discovery of new effective medical molecules and their implementation in the daily clinical practice of the intensive care unit remains a major hurdle. Fortunately, ongoing research continues to provide new information on the management of sepsis, in particular, severe sepsis or septic shock. High quality and effective management tools are necessary to bring evidence-based therapy to the bedside. On this basis, new therapies could be tested to reduce mortality rates with respect to recently published studies.
多年来,采用相对直接的病理生理方法进行的基础研究推动了使用据称能积极干预炎症过程的分子开展的临床试验。然而,这些试验大多未能证明有任何预后益处。事实上,我们需要重新审视当前的范式,并思考在严重脓毒症或脓毒性休克中预后可能预先确定的可能性。此外,在临床衰退发作之前早期诊断脓毒症也特别受到医疗从业者的关注,因为这一信息增加了对这种危及生命的病症进行早期和特异性治疗的可能性。确实,开始治疗的时机被认为至关重要,并且是脓毒症存活的主要决定因素。尽管脓毒症治疗取得了重大进展,但新的有效医学分子的发现与它们在重症监护病房日常临床实践中的应用之间的差距仍然是一个主要障碍。幸运的是,正在进行的研究继续提供有关脓毒症管理的新信息,特别是严重脓毒症或脓毒性休克。高质量和有效的管理工具对于将循证治疗应用于床边是必要的。在此基础上,可以测试新的疗法以相对于最近发表的研究降低死亡率。